Larimar Therapeutics, INC Form 4 insider transactions

Larimar Therapeutics Director Thomas Edward Hamilton reported the acquisition of 50,000 shares of common stock.

Director Jonathan S. Leff, representing Deerfield Management, was granted 55,150 stock options in Larimar Therapeutics.

Director Jonathan S. Leff was granted 55,150 stock options in Larimar Therapeutics, Inc. as part of his board service.

Larimar Therapeutics, Inc. reports that Director Joseph Truitt was granted stock options on May 19, 2026, with vesting contingent on continued service.

Larimar Therapeutics Director Thomas Frank E. acquired 55,150 stock options with an exercise price of $3.33, vesting on May 19, 2027, or the next annual meeting.

Larimar Therapeutics Director Thomas Edward Hamilton acquired 55,150 stock options with an exercise price of $3.33, vesting on May 19, 2027, or the next annual meeting.

Deerfield Management entities, including Director James E. Flynn, significantly increased their holdings in Larimar Therapeutics, acquiring 5 million shares for $25 million.

Larimar Therapeutics Director Thomas Edward Hamilton acquired 100,000 shares of common stock at $5 per share in a recent underwritten offering.

Larimar Therapeutics Director Jeffrey W. Sherman reported a planned acquisition of 5,000 common shares at $5 each.

Larimar Therapeutics' Chief Development Officer, Gopi Shankar, acquired 25,637 restricted stock units and 153,822 stock options.

Russell Clayton, Chief Medical Officer of Larimar Therapeutics, was granted 25,637 restricted stock units and options to purchase 153,822 shares of common stock.

Larimar Therapeutics' President and CEO, Carole Ben-Maimon, reported the acquisition of 100,100 restricted stock units and 600,600 stock options.

Larimar Therapeutics' CFO Michael Celano received grants of 37,604 restricted stock units and options to purchase 225,622 shares of common stock.

Deerfield Management and affiliated funds have significantly increased their beneficial ownership in Larimar Therapeutics by purchasing common stock at $3.2 per share on July 31, 2025.

Deerfield Management, through director Jonathan S. Leff, acquired 19,000 stock options in Larimar Therapeutics, Inc.

Jeffrey W. Sherman, a director at Larimar Therapeutics, acquired 19,000 stock options on May 13, 2025, exercisable at $1.875.

Director Joseph Truitt acquired 19,000 stock options in Larimar Therapeutics, Inc. on May 13, 2025.

Director Thomas Edward Hamilton acquired 19,000 stock options in Larimar Therapeutics on May 13, 2025.

Frank E. Thomas, a director at Larimar Therapeutics, acquired 19,000 stock options on May 13, 2025, exercisable at $1.875.

Director Jonathan S. Leff acquired 19,000 stock options in Larimar Therapeutics, Inc. on May 13, 2025.

Larimar Therapeutics' Chief Development Officer, Gopi Shankar, acquired shares and stock options on January 22, 2025, according to a recent SEC filing.

Larimar Therapeutics' Chief Medical Officer, Russell Clayton, acquired 23,306 shares of common stock and 139,838 stock options on January 22, 2025.

Larimar Therapeutics CEO Carole Ben-Maimon acquired 91,000 restricted stock units and 546,000 stock options on January 22, 2025.

Michael Celano, CFO of Larimar Therapeutics, reports the acquisition of stock options and restricted stock units.

James E. Flynn, a director by deputization of Larimar Therapeutics, reports the acquisition of stock options through Deerfield Management Company, L.P.

Director Frank E. Thomas acquired 19,000 stock options in Larimar Therapeutics, Inc. on May 29, 2024.

Jonathan S. Leff, a director of Larimar Therapeutics, acquired 19,000 stock options on May 29, 2024, according to a recent SEC filing.

Jeffrey W. Sherman, a director of Larimar Therapeutics, acquired 19,000 stock options on May 29, 2024, according to a recent SEC filing.

Director Joseph Truitt acquired 19,000 stock options in Larimar Therapeutics, Inc. on May 29, 2024.

Director Thomas Edward Hamilton purchased 57,208 shares of Larimar Therapeutics in a recent underwritten offering.